Weizmann Institute of Science
- Country
- 🇮🇱Israel
- Ownership
- Private
- Established
- 1934-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.weizmann.ac.il
Clinical Trials
12
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Replacing Bone Marrow With Peripheral Blood in Cytopenia Patients
- Conditions
- Cytopenia
- First Posted Date
- 2025-07-23
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- Weizmann Institute of Science
- Target Recruit Count
- 1500
- Registration Number
- NCT07081087
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
The Role of Microbiome in Recurrent Obesity Before and After Antibiotic/Placebo Treatment
- Conditions
- ObesityWeight Loss
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Weizmann Institute of Science
- Target Recruit Count
- 200
- Registration Number
- NCT06681246
- Locations
- 🇮🇱
Weizmann Institute of Science, Reẖovot, Israel
Decoding the Clinical Impact of Host and Microbial Intestinal Proteomic Landscape in Crohn's Disease
- Conditions
- Crohn Disease
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Weizmann Institute of Science
- Target Recruit Count
- 40
- Registration Number
- NCT06494826
- Locations
- 🇮🇱
Emek medical center, Afula, Israel
The Stool Microbiome of Treated and Untreated IBS (Irritable Bowel Syndrome) Patients
- Conditions
- Irritable Bowel Syndrome
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Weizmann Institute of Science
- Target Recruit Count
- 200
- Registration Number
- NCT05972317
- Locations
- 🇮🇱
Weizmann institute of science, Rehovot, Israel
Human Phenotype Project Study Protocol
- Conditions
- Adult Disease
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Weizmann Institute of Science
- Target Recruit Count
- 30000
- Registration Number
- NCT05817734
- Locations
- 🇮🇱
Weizmann institute of science, Reẖovot, Israel
- Prev
- 1
- 2
- 3
- Next
News
ImPact Biotech's Padeliporfin VTP Therapy Enables Surgical Resection in Previously Inoperable Pancreatic Cancer Patient
ImPact Biotech's first patient in a Phase 1 trial of Padeliporfin VTP therapy for locally advanced pancreatic ductal adenocarcinoma successfully underwent surgical resection after being initially deemed inoperable.
ImPact Biotech to Present Promising Data on Padeliporfin VTP for UTUC and Prostate Cancer at AUA 2025
ImPact Biotech will present updated preliminary results from the ENLIGHTED Phase 3 study evaluating Padeliporfin VTP as a non-invasive treatment option for low-grade upper tract urothelial cancer at AUA 2025.
IPL344 Shows Promising Results in Slowing ALS Progression in Phase 2a Trial
Immunity Pharma's IPL344 demonstrated a 58-64% slower ALSFRS-R progression rate in ALS patients compared to matched historical controls, with statistical significance (p=0.034).
ImPact Biotech Reports 77% Complete Response Rate for Padeliporfin VTP in Low-Grade Upper Tract Urothelial Cancer
ImPact Biotech's Phase 3 ENLIGHTED trial demonstrated a 77% complete response rate (10/13 patients) for Padeliporfin VTP therapy in low-grade upper tract urothelial cancer patients who completed the induction treatment phase.